JP2008536930A5 - - Google Patents

Download PDF

Info

Publication number
JP2008536930A5
JP2008536930A5 JP2008507782A JP2008507782A JP2008536930A5 JP 2008536930 A5 JP2008536930 A5 JP 2008536930A5 JP 2008507782 A JP2008507782 A JP 2008507782A JP 2008507782 A JP2008507782 A JP 2008507782A JP 2008536930 A5 JP2008536930 A5 JP 2008536930A5
Authority
JP
Japan
Prior art keywords
cells
cell
composition
relatively pure
ischemic tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008507782A
Other languages
Japanese (ja)
Other versions
JP2008536930A (en
JP4659092B2 (en
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/014445 external-priority patent/WO2006113647A2/en
Publication of JP2008536930A publication Critical patent/JP2008536930A/en
Publication of JP2008536930A5 publication Critical patent/JP2008536930A5/ja
Application granted granted Critical
Publication of JP4659092B2 publication Critical patent/JP4659092B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (11)

動物又はヒトの損傷した虚血性組織を治療するための組成物であって、
薬学的に許容可能なキャリア中の比較的純粋な単離された自己のＢ細胞集団を含み、
前記組成物の量は、損傷した虚血性組織を治療するのに有効な量であり、
前記比較的純粋な単離されたＢ細胞集団は、
幹細胞及びＢ細胞を含む不均質の細胞集団から幹細胞を実質的に除去して、比較的純粋なＢ細胞の集団を得る工程により調製される、組成物。 A composition for treating damaged ischemic tissue in an animal or human comprising
A relatively pure isolated autologous B cell population in a pharmaceutically acceptable carrier,
The amount of the composition is an amount effective to treat damaged ischemic tissue;
The relatively pure isolated B cell population is
A composition prepared by substantially removing stem cells from a heterogeneous cell population comprising stem cells and B cells to obtain a relatively pure population of B cells. 更に、動物又はヒトの損傷した虚血性組織においてＢ細胞密度を増加させる物質を含有する、請求項１に記載の組成物。   2. The composition of claim 1 further comprising a substance that increases B cell density in ischemic tissue injured in animals or humans. 更に、前記損傷した虚血性組織の機能の回復、又は動物もしくはヒトへ投与される比較的純粋なＢ細胞集団の機能もしくは生存を促進する物質を含有する、請求項１又は２に記載の組成物。   The composition according to claim 1 or 2, further comprising a substance that promotes restoration of the function of the damaged ischemic tissue or the function or survival of a relatively pure B cell population administered to an animal or human. . 前記Ｂ細胞が骨髄、リンパ節、脾臓又は血液に由来するものである、請求項１〜３の何れか１項に記載の組成物。   The composition according to any one of claims 1 to 3, wherein the B cell is derived from bone marrow, lymph node, spleen or blood. 前記Ｂ細胞がＣＤ１９+細胞、Ｂ２２０+細胞又はＢ細胞受容体（Ｉｇαβ）+細胞あるいはそれらの組合せである、請求項１〜４のいずれか１項に記載の組成物。 The composition according to any one of claims 1 to 4, wherein the B cell is a CD19 + cell, a B220 + cell, a B cell receptor (Igαβ) + cell, or a combination thereof. 前記損傷した虚血性組織が心臓組織である、請求項１〜５のいずれか１項に記載の組成物。   The composition according to any one of claims 1 to 5, wherein the damaged ischemic tissue is heart tissue. 動物又はヒトの損傷した虚血性組織を治療するための組成物を生産する方法であって、損傷組織を有する動物又はヒトから得られたＢ細胞を含有するサンプルを精製し、比較的純粋な単離されたＢ細胞を生産する工程、
前記比較的純粋な単離されたＢ細胞を薬学的に許容可能なキャリアと組み合わせて、組成物を調製する工程を含み、
前記比較的純粋な単離されたＢ細胞集団が、幹細胞及びＢ細胞を含有する不均質の細胞集団から幹細胞を実質的に除去して、比較的純粋なＢ細胞の集団を得ることを含む方法により調製される、
動物又はヒトの損傷した虚血性組織を治療するための組成物を生産する方法。 A method for producing a composition for treating damaged ischemic tissue in an animal or human, the method comprising purifying a sample containing B cells obtained from an animal or human having damaged tissue, Producing detached B cells;
Combining the relatively pure isolated B cells with a pharmaceutically acceptable carrier to prepare a composition;
The relatively pure isolated B cell population comprises substantially removing stem cells from the heterogeneous cell population containing stem cells and B cells to obtain a relatively pure population of B cells. Prepared by
A method of producing a composition for treating damaged ischemic tissue in an animal or human. 更に、損傷した虚血性組織の機能の回復、又は動物もしくはヒトへ投与された、比較的純粋なＢ細胞集団の機能もしくは比較的純粋なＢ細胞集団の生存を促進する物質を加える工程を含む、
請求項７に記載の組成物を生産する方法。 And adding a substance that promotes restoration of the function of the damaged ischemic tissue or the function of the relatively pure B cell population or the survival of the relatively pure B cell population administered to an animal or human.
A method for producing the composition of claim 7. 前記Ｂ細胞が骨髄、リンパ節、脾臓又は血液に由来するものである、請求項７又は８に記載の方法。   The method according to claim 7 or 8, wherein the B cell is derived from bone marrow, lymph node, spleen or blood. 前記Ｂ細胞を含有するサンプルが、ＣＤ１９+細胞、Ｂ２２０+細胞又はＢ細胞受容体（Ｉｇαβ）+細胞あるいはそれらの組合せである、請求項７〜９のいずれか１項に記載の方法。 The method according to any one of claims 7 to 9, wherein the sample containing B cells is CD19 + cells, B220 + cells or B cell receptor (Igαβ) + cells or a combination thereof. 前記損傷した虚血性組織が心臓組織である、請求項７〜１０のいずれか１項に記載の方法。   11. The method according to any one of claims 7 to 10, wherein the damaged ischemic tissue is heart tissue.
JP2008507782A 2005-04-18 2006-04-18 Recovery of tissue function by administration of B cells to damaged tissue Active JP4659092B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67241605P 2005-04-18 2005-04-18
PCT/US2006/014445 WO2006113647A2 (en) 2005-04-18 2006-04-18 Recovery of tissue function following administration of b cells to injured tissue

Publications (3)

Publication Number Publication Date
JP2008536930A JP2008536930A (en) 2008-09-11
JP2008536930A5 true JP2008536930A5 (en) 2010-07-15
JP4659092B2 JP4659092B2 (en) 2011-03-30

Family

ID=37115830

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008507782A Active JP4659092B2 (en) 2005-04-18 2006-04-18 Recovery of tissue function by administration of B cells to damaged tissue

Country Status (5)

Country Link
US (2) US7695712B2 (en)
EP (1) EP1877544B1 (en)
JP (1) JP4659092B2 (en)
AT (1) ATE537249T1 (en)
WO (1) WO2006113647A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9220813B2 (en) * 2005-04-18 2015-12-29 Holy Cross Hospital, Inc. Cell therapy for limiting overzealous inflammatory reactions in tissue healing
JP4659092B2 (en) * 2005-04-18 2011-03-30 エーシーティーエックス，インコーポレイテッド Recovery of tissue function by administration of B cells to damaged tissue
WO2008103336A1 (en) * 2007-02-21 2008-08-28 Cook Incorporated Methods for intravascular engraftment in heart
KR101922118B1 (en) 2012-08-27 2018-11-26 삼성전자주식회사 Flexible semiconductor device and method of manufacturing the same
EP2943206A4 (en) 2013-01-12 2017-01-04 Cesca Therapeutics Inc. Rapid infusion of autologous bone marrow derived stem cells
EP3593810B1 (en) 2013-10-28 2021-06-23 Biocardia, Inc. Methods of measuring potential for therapeutic potency and defining dosages for autologous cell therapies
US9775816B2 (en) 2013-11-07 2017-10-03 The General Hospital Corporation Eluting matrix and uses thereof
CN113677354A (en) * 2019-01-23 2021-11-19 综合医院公司 B cell immunotherapy
US20230158074A1 (en) * 2020-04-16 2023-05-25 The General Hospital Corporation B cell immunomodulatory therapy for acute respiratory distress syndrome

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6465251B1 (en) * 1996-11-13 2002-10-15 Dana-Farber Cancer Institute, Inc. Method of promoting b-cell proliferation and activation with CD40 ligand and cyclosporin
WO2004044584A1 (en) 2002-11-13 2004-05-27 Micromet Ag Method for identifying antigen specific b cells
JP4659092B2 (en) * 2005-04-18 2011-03-30 エーシーティーエックス，インコーポレイテッド Recovery of tissue function by administration of B cells to damaged tissue

Similar Documents

Publication Publication Date Title
JP2008536930A5 (en)
Dan et al. The influence of cellular source on periodontal regeneration using calcium phosphate coated polycaprolactone scaffold supported cell sheets
RU2009100930A (en) MEDICINES FOR STIMULATING HEMOPOETIC STEM CELL GROWTH
NZ597965A (en) Methods of preparing and using stem cell compositions and kits comprising the same
DE69941903D1 (en) TREATMENT OF PATIENTS OBTAINING BONE MARROW TRANSPLANTATION OR TRANSPLANTATION OF PERIPHERAL BLOOD TEMM CELLS WITH ANTI-CD20 ANTIBODIES
Jacotti et al. Ridge augmentation with mineralized block allografts: clinical and histological evaluation of 8 cases treated with the 3-dimensional block technique
WO2004009767A3 (en) Cell therapy for regeneration
Khademi et al. Periodontal healing of replanted dog teeth stored in milk and egg albumen
Ghanaati et al. Implantation of silicon dioxide-based nanocrystalline hydroxyapatite and pure phase beta-tricalciumphosphate bone substitute granules in caprine muscle tissue does not induce new bone formation
JP2010518946A5 (en)
JP2013500823A (en) Method of processing alveolar bone graft material and alveolar bone graft material, and treatment method using the above alveolar bone graft material
JP2002524421A5 (en)
Manimaran et al. Regeneration of mandibular ameloblastoma defect with the help of autologous dental pulp stem cells and buccal pad of fat stromal vascular fraction
RU2008152746A (en) TREATMENT OF ISCHEMIC DISEASES USING ERYTHROPOETIN
Yang et al. A novel possible strategy based on self‐assembly approach to achieve complete periodontal regeneration
ATE449165T1 (en) MULTIPOTENT BLOOD STEM CELLS FROM THE UMBILE CORD AND CELL TREATMENT AGENTS THEREFOR FOR THE TREATMENT OF ISCHEMIC DISEASE
AR085141A1 (en) A METHOD FOR EXTENDING THE SURVIVAL OF A RENAL PAD, USE OF AN ANTIBODY ANTI-CD200 TO EXTEND THE SURVIVAL OF PADS
Ohba et al. Onlay bone augmentation on mouse calvarial bone using a hydroxyapatite/collagen composite material with total blood or platelet-rich plasma
CN100341529C (en) Combination of Tibet medicine of containing salt and possessing medicinal effect health care, and preparation metohd
JP2016524989A5 (en)
RU2545993C2 (en) Method for repairing long bone defects of critical size
WO2003059375A1 (en) Complex therapy for tissue regeneration
JP2002534393A5 (en)
US20070140988A1 (en) Therapeutic agent for periodontal disease
JP2007020682A (en) Cell semination method